Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06257537
Other study ID # KP-01-2024
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date February 19, 2024
Est. completion date February 28, 2025

Study information

Verified date February 2024
Source ZetrOZ, Inc.
Contact George K Lewis, Ph.D.
Phone 8882029831
Email george@zetroz.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the ability of long-duration low intensity therapeutic ultrasound (LITUS) to alleviate knee Osteoarthritis pain over a 24-week period. The primary objective of this study is to evaluate the analgesic effect of LITUS in subjects suffering from knee Osteoarthritis pain. Secondary objectives are to assess the ability of LITUS to improve joint function.


Description:

This is a 24-week study to clinically evaluate the effectiveness of the wireless Sustained Acoustic Medicine (SAM) device combined with diclofenac on symptoms of patients suffering from knee osteoarthritis. The class-II device, samĀ®, has been FDA-cleared for home use. On the first day of the study, baseline data will be collected as patients report pain score before treatment. During the following 24 weeks, patients will self-apply their assigned treatment for the 4 hours daily. Each day of the study, pain scores will be recorded immediately before application of SAM device as well as at the completion of treatment. Assessments on quality of life & function, depression & anxiety, and sleep will be performed prior to the patient beginning the protocol, at 8 weeks, 16 weeks and at the conclusion of the protocol. Over 300 subjects will be recruited from neighboring communities to the study sites. The study is designed to reach a target patient population which includes rural citizens and socioeconomic disadvantaged individuals.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 300
Est. completion date February 28, 2025
Est. primary completion date December 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 25 Years to 85 Years
Eligibility Inclusion Criteria: - Have physician-diagnosed mild to moderate knee OA (OARSI atlas grades 1-2) - Fulfill the American College of Rheumatology clinical and radiological diagnostic criteria for knee OA - Are between 25-85 years of age - Report a frequent pain score between 4-7 (range: 0-10) during the week preceding enrollment - Report that knee pain negatively affects quality of life - Are willing not to use any cream, gel, or topical solution during the administration of treatment other than the approved ultrasound gel provided to the subject at the initiation of the study - Are deemed appropriate by their physician or by the study site physician to participate. - Be willing and able to self-administer treatment daily within their place of residence or during normal daily activity, excluding bathing, showering, or other water activities which may result in submersion of the study device. - Not use or initiate use of opioid and/or non-opioid analgesic medications. - Be willing to discontinue any other interventional treatment modalities on the knee during the study period (e.g., transcutaneous electrical nerve stimulation, electronic muscle stimulation, traditional ultrasound). Exclusion Criteria: - Cannot successfully demonstrate the ability to put on and take off the device. - Displays any condition which, in the judgment of the investigator, would make participation in the study unacceptable including, but not limited to, the subject's ability to understand and follow instructions. - Participated in a clinical trial for an investigational drug and/or agent within 30 days prior to screening. - Is pregnant. - Is a prisoner. - Is non-ambulatory (unable to walk). - Has a pacemaker. - Has a malignancy in the treatment area. - Has an active infection, open sores, or wounds in the treatment area. - Has impaired sensation in the treatment area, such as caused by chemotherapy or anesthesia. - Has a known neuropathy (disease of the brain or spinal nerves). - Has a hereditary disposition (tendency) for excessive bleeding (hemorrhage). - Have knee replacement, other surgical intervention, or hyaluronidase injection in the affected knee in the past 6 months. - Are currently taking steroids. - Have any contraindication to radiograph. - Have a secondary cause of arthritis (metabolic or inflammatory).

Study Design


Intervention

Device:
Sustained Acoustic Device with 2.5% Diclofenac Patch
Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm^2 with 2.5% Diclofenac patches.
Sustained Acoustic Device with 0% Diclofenac Patch
Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% diclofenac patches.
Drug:
2.5% Diclofenac Patches
Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.
Other:
SAM Patch
Ultrasound gel without additional pain relief medication worn for 4 hours at least 5 days a week via SAM patch.

Locations

Country Name City State
United States Cayuga Medical Center - Medical Pain Consultants Dryden New York
United States Orthopaedic Foundation Stamford Connecticut
United States ZetrOZ Systems Trumbull Connecticut

Sponsors (1)

Lead Sponsor Collaborator
ZetrOZ, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Pain Units on a Scale (0-10) 0 Being Least, 10 Being Worst Pain From Baseline Change in the self-described pain units on a scale by patient at baseline and post-treatment. Through study completion, average of 24 weeks.
Primary Change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) WOMAC questionnaire will be utilized (Western Ontario and McMaster Universities Arthritis Index) at baseline and post-treatment to calculate the change in scores. WOMAC was divided into 3 categories: pain, stiffness, function and total score. The pain category consists of five scores from 0 - 4, 0 being no pain 4 is worst pain possible, for a range of 0 - 20 points. The stiffness category consists of two scores from 0 - 4, 0 being no stiffness 10 is worst stiffness possible for a range of 0 - 8 points. The function score consists of 17 scores from 0 - 4, 0 being normal function and 10 is severely limited function, for a range of 0 - 68 points. Total score is the sum of pain, stiffness, and function scores (range of 0 - 96). Through study completion, average of 24 weeks.
Secondary Change in Global Rating of Change (GROC) on a Scale (-7 to +7) Subject-reported change in overall pain on a scale, -7 = worst, +7 = best. Through study completion, average of 24 weeks.
Secondary Change in the Pain & Sleep Questionnaire (PSQ-3) Subject-reported rating of impact of pain on sleep on a scale from 0 no impact, to 100 greatest impact. Through study completion, average of 24 weeks.
Secondary Change in Depression Anxiety Stress Scale (DASS21) Subject-reported measures of depression, anxiety, and stress on a scale of 0-3, 0 being not applicable, 1 meaning applicable to some degree, 2 meaning applicable often, and 3 meaning applicable most of the time. Questions are divided into three categories: depression, anxiety, and stress. Through study completion, average of 24 weeks.
See also
  Status Clinical Trial Phase
Completed NCT04228458 - ThermRheum Version 1 N/A
Withdrawn NCT04976972 - A Comparison of Patients Receiving a Total Knee Replacement With Robotic Assistance or With Conventional Instrumentation N/A
Completed NCT04037436 - Functional Exercise and Nutrition Education Program for Older Adults N/A
Completed NCT00069342 - Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases
Completed NCT02944448 - A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee Phase 2
Recruiting NCT02498808 - Interferon-lambda: Novel Biologics for Controlling Neutrophil-mediated Pathology in Rheumatic Diseases? N/A
Recruiting NCT02777060 - Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures N/A
Enrolling by invitation NCT02487888 - A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient Care N/A
Withdrawn NCT02136251 - Total Shoulder Replacement Outcomes With Autologous Bone Graft as Fixator for Glenoid Anchor Peg.
Completed NCT02143206 - Modifying Exercise for the COPD Patient
Completed NCT01407874 - A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency Phase 2
Completed NCT01285843 - Periprosthetic Bone Mineral Density After Total Hip Arthroplasty Performed Through a Minimally Invasive Anterior Approach (AMIS) With Either an AMIStem or a Quadra Femoral Component N/A
Completed NCT01172327 - Self-Directed Exercise Program for Adults With Arthritis N/A
Completed NCT00987870 - Safety and Efficacy of BFH772 in Psoriasis Patients Phase 1/Phase 2
Completed NCT00750984 - A Comparison of Two Different Surgical Techniques for Total Hip Resurfacing N/A
Completed NCT01184924 - Evaluation of the Arthritis Foundation Tai Chi Program N/A
Active, not recruiting NCT00611585 - A Safety and Efficacy Study of the Birmingham Hip Resurfacing System N/A
Completed NCT00379184 - Sensitization in Osteoarthritic Knees N/A
Completed NCT00403676 - Nursing Consultation in Out-patient Clinics for Patients With Inflammatory Rheumatic Disease N/A
Completed NCT00175448 - Comparison of Physiotherapy Versus Home Exercise Following Hip Replacement Surgery N/A

External Links